http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Sung Jo Yuh (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
비소세포폐암에서 동시화학방사선요법을 받는 중 생긴 기관폐루1례
강건희,조성우,김성록,유영진,이효락 인제대학교 2008 仁濟醫學 Vol.29 No.-
최근 근치적 절제가 불가능한 국소진행성 비소세포 폐암에서 화학요법을 방사선요법과 동시에 투여하는 치료방법에 대한 연구가 활발이 이루어지고 있으며 이러한 치료과정 중 생긴 여러 부작용에 대한 연구도 이루어지고 있지만 아직까지 기관폐루가 생겼다고 보고는 없다. 따라서 치료과정 중 기관폐루가 의심되는 소견이 있을 경우 이에 대한 조기 진단과 치료를 통하여 부작용에 따른 사망률을 최소화하여야 하겠다. The incidence of lung cancer is increasing steadily and various methods have been attempted to enhance the cure rate of locally advanced non small cell lung cancer, which is hardly removable surgically, but the results are not satisfactory yet. Recently, research is being made actively on the simultaneous application of chemotherapy and radiotherapy for locally advanced non small cell lung cancer that cannot be radically resected and the we experienced a case of patient diagnosed with bronchopulmonary fistula during the treatment process, and therefore report it here.
-
Seo-Yeon Ahn,Sang Kyun Son,Gyu Hyung Lee,Inho Kim,June-Won Cheong,Won Sik Lee,Byung Soo Kim,Deog-Yeon Jo,Chul Won Jung,Chu Myoung Seong,Jae Hoon Lee,Young Jin Yuh,Min Kyoung Kim,Hun-Mo Ryoo,Moo-Rim Pa 대한혈액학회 2022 Blood Research Vol.57 No.2
Background Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical practice within South Korea. Methods An open-label, multicenter, single-arm, 12-week observational post-marketing surveillance (PMS) study was conducted on 669 Korean adult patients with Ph+ CML from December 24, 2010, to December 23, 2016. The patients received nilotinib treatment in routine clinical practice settings. Safety was evaluated by all types of adverse events (AEs) during the study period, and efficacy was evaluated by the complete hematological response (CHR) and cytogenetic response. Results During the study period, AEs occurred in 61.3% (410 patients, 973 events), adverse drug reactions (ADRs) in 40.5% (271/669 patients, 559 events), serious AEs in 4.5% (30 patients, 37 events), and serious ADRs in 0.7% (5 patients, 8 events). Furthermore, unexpected AEs occurred at a rate of 6.9% (46 patients, 55 events) and unexpected ADRs at 1.2% (8 patients, 8 events). As for the efficacy results, CHR was achieved in 89.5% (442/494 patients), and minor cytogenetic response or major cytogenetic response was achieved in 85.8% (139/162 patients). Conclusion This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph+ CML in routine clinical practice settings.
-
Is S1 Alar Iliac Screw a Feasible Option for Lumbosacral Fixation?: A Technical Note
Zhi Wang,Ghassan Boubez,Daniel Shedid,Sung Jo Yuh,Amer Sebaaly 대한척추외과학회 2018 Asian Spine Journal Vol.12 No.4
Nonunion at the lumbosacral junction is a classic complication of long construct and deformity corrections. Iliac fixations have been extensively studied in the literature and have demonstrated superior biomechanical proprieties and lower complication rates. S2 alar iliac screws address the drawbacks of classical iliac screws but demonstrate similar biomechanical advantage. The main aim of this paper was to describe the S1 alar iliac (S1AI) screw fixation technique while evaluating our early results. S1AI screw fixation technique has the advantage of being able to achieve pelvic fixation without dissection to the S2 pedicle entry and is therefore a viable option for salvage of a failed S1 promontory screw.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
